Development and Validation of a Tumor Mutation Burden–Related Immune Prognostic Model for Lower-Grade Glioma
Tumor mutation burden (TMB) is a useful biomarker to predict prognosis and the efficacy of immune checkpoint inhibitors (ICIs). In this study, we aimed to explore the prognostic value of TMB and the potential association between TMB and immune infiltration in lower-grade gliomas (LGGs). Somatic muta...
Main Authors: | Wen Yin, Xingjun Jiang, Jun Tan, Zhaoqi Xin, Quanwei Zhou, Chaohong Zhan, Xianyong Fu, Zhaoping Wu, Youwei Guo, Zhipeng Jiang, Caiping Ren, Guihua Tang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.01409/full |
Similar Items
-
Molecular Subtypes Based on the Stemness Index Predict Prognosis in Glioma Patients
by: Jun Tan, et al.
Published: (2021-03-01) -
Expression and clinical significance of RBBP4 gene in lower-grade glioma: An integrative analysis
by: Ruofei Liang, et al.
Published: (2023-09-01) -
Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy
by: Chubei Teng, et al.
Published: (2022-05-01) -
Integrated analysis of necroptosis related gene signature to predict clinical outcomes, immune status and drug sensitivity in lower grade Glioma
by: Xiqi Hu, et al.
Published: (2024-01-01) -
The copper-associated protein STEAP2 correlated with glioma prognosis and immune infiltration
by: Xu Wang, et al.
Published: (2022-08-01)